Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Catalyst Pharma (CPRX – Research Report), ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

This is the 2 nd orphan drug designation granted to the skeletal muscle-specific drug therapy NMD670 Under this newly granted orphan drug designation, NMD670 is currently being evaluated in a Phase 2 ...

After Donald Trump suggested he might take over Greenland by force, the consensus among the island’s population appears to be bewilderment and anxiety. By Jeffrey Gettleman and Maya Tekeli The ...